Skip to main content
Premium Trial:

Request an Annual Quote

Cenix to Use Definiens' Cellenger System

NEW YORK (GenomeWeb News) – RNAi research services company Definiens said today that Cenix BioScience has expanded a license agreement to continue to use Definiens’ data extraction technology in its microscopy assays for high throughput RNAi studies in human and rodent cells.
 
Under the agreement, Cenix will integrate the Definiens Cellenger system into its existing high-throughput and high-content RNAi-based research infrastructure, the company said.
 
The Cellenger system is an application for high content analysis that enables fully automated extraction of data from images in cell-based assays. Using the system allows Cenix to accurately study “subjects of interest even in complex images with high accuracy.”
 
Financial terms of the agreement were not released.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.